Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
Malagola M, Iurlo A, Bucelli C, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, De Gobbi M, Romano A, Tiribelli M, Russo Rossi A, Russo S, Defina M, Farina M, Bernardi S, Butturini G, Pellizzeri S, Roccaro AM, Russo D. Malagola M, et al. Among authors: iurlo a. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):323-331. doi: 10.1016/j.clml.2024.01.008. Epub 2024 Jan 25. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38369436 Free article. Clinical Trial.
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E, Cacciola R, Candoni A, Crugnola M, Codeluppi K, Usala E, Specchia G, Martinelli V, Palmieri F, Pierri I, Liberati AM, Iurlo A, Grossi A, Vannucchi AM, Vianelli N, Mazzucconi MG. Gugliotta L, et al. Among authors: iurlo a. Leuk Res. 2011 Dec;35(12):1557-63. doi: 10.1016/j.leukres.2011.06.030. Epub 2011 Jul 20. Leuk Res. 2011. PMID: 21764130
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Latagliata R, et al. Among authors: iurlo a. Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Hematol Oncol. 2013. PMID: 22815278
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Latagliata R, et al. Among authors: iurlo a. Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6. Drugs Aging. 2013. PMID: 23681399
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D. Malagola M, et al. Among authors: iurlo a. Am J Hematol. 2014 Feb;89(2):119-24. doi: 10.1002/ajh.23593. Am J Hematol. 2014. PMID: 24122886 Free article.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G. Breccia M, et al. Among authors: iurlo a. Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7. Leuk Res. 2014. PMID: 25047978
Differences among young adults, adults and elderly chronic myeloid leukemia patients.
Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Among authors: iurlo a. Ann Oncol. 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361995 Free article. Clinical Trial.
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Castagnetti F, et al. Among authors: iurlo a. Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19. Leukemia. 2015. PMID: 26088952 Clinical Trial.
281 results